Broncus HoldingBRNHF 39 Operating Margin % is 916.31% as of Dec. 2025. GuruFocus rates BRNHF with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Broncus Holding ranks worse than 98.77% on this metric.
Broncus Holding Corp operating margin has been in a 5-year decline. The average rate of decline per year is -48.8%.
The historical rank and industry rank for Broncus Holding's Operating Margin % or its related term are showing as below:
BRNHF'
s Operating Margin % Range Over the Past 10 Years
Min: -12610.19 Med: -337.54 Max: -243.4
Current: -11685.61
BRNHF's Operating Margin % is ranked worse than 98.77% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs BRNHF: -11685.61
Broncus Holding's 5-Year Average Operating Margin % Growth Rate was -48.80% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Broncus Holding Operating Margin % Related Terms
Broncus Holding Operating Margin % Historical Data
* Premium members only.
The historical data trend for Broncus Holding's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRNHF vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, Broncus Holding's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Broncus Holding's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Broncus Holding's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding (BRNHF) has a Operating Margin % of 916.31% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Broncus Holding and its competitors. According to the industry distribution chart, Broncus Holding ranks #806 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98.8%.
Is Broncus Holding's Operating Margin % too high?
Broncus Holding's current Operating Margin % is 916.31%. The Medical Devices & Instruments industry median Operating Margin % is 3.47. Broncus Holding's value of 916.31% is 26344.7% above this industry median. Based on the distribution chart, Broncus Holding ranks #806 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Broncus Holding has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Broncus Holding ranks #806 out of 816 companies for Operating Margin %. This places Broncus Holding in the lower half of its industry. The industry median Operating Margin % is 3.47. Broncus Holding's value of 916.31% is 26344.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Broncus Holding's current Operating Margin % of 916.31% is 26344.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Broncus Holding and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Broncus Holding's current Operating Margin % is 916.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Broncus Holding (BRNHF) has a current Operating Margin % of 916.31%. The current Operating Margin % is 916.31% and 26344.7% above the Medical Devices & Instruments industry median of 3.47. Broncus Holding's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Broncus Holding (BRNHF), the current Operating Margin % is 916.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
39GF Score
Get the complete analysis for BRNHF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRNHF has been successfully added to your 
